Targeting Cell Cycle Checkpoints in Glioma

Targeting Cell Cycle Checkpoints in Glioma

Targeting Cell Cycle Checkpoints in Glioma


Dr. Lisa Porter

University of Windsor

|

Dr. Ana DeCarvalho

Henry Ford Health System

 

Glioblastoma multiforme is an aggressive brain cancer of which there are currently no effective treatment options. Glioblastoma cells have very rapid mutation rates and the tumour itself is comprised of a mix of different cells with differing capabilities of driving tumour recurrence. Research has shown that only a small population of cells (called Brain Tumourliniating Cells; BTICs) within the tumour are the most deadly, but these cells are also insensitive to available therapies. The Porter Lab has found a protein, called Spy1, that is important in the expansion of the BTIC population. Spy1 is highly expressed in patients with glioblastoma, and early pre-clinical data suggests that targeting its mechanism may make an exciting therapy for these patients. This project will test the potential of targeting Spy1 for treatment of this aggressive form of cancer.

Related Programs:
Nucleus Cores:

FUNDER:

Canadian Institutes of Health Research (CIHR)

FUNDING:

$1 million

GRANT DURATION:

2019-2023

 

WE SPARK COLLABORATORS

University of Windsor

  • Dr. Abdulkadir Hussein
  • Dr. John Trant
  • Dr. Otis Vacratsis

Windsor Regional Hospital

COLLABORATORS

Lunenfeld-Tanenbaum Research Institute

  • Dr. Daniel Schramek

Michigan State University

  • Dr. Eran Andrecheck
  • Dr. Swati Kulkarni
  • Dr. Abdalla Shamisa
Loading...